Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA) (MTA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00000388 |
Recruitment Status :
Completed
First Posted : November 3, 1999
Last Update Posted : September 29, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This trial is a continuation of the Multimodal Treatment Study of Children with Attention Deficit Hyperactivity Disorder (MTA Study). Continuation Aim 1 is to track the persistence of intervention-related effects as the MTA sample matures into mid-adolescence, including subsequent mental-health and school-related service utilization patterns as a function of MTA treatment experience (treatment assignment) and outcome (degree of treatment success at 14 mo.). Aim 2 is to test specific hypotheses about predictors, mediators, and moderators of long-term outcome among children with ADHD (e.g., comorbidity; family functioning; cognitive skills; peer relations) that may influence adolescent functioning (either independent of or through initial treatment assignment and/or 14-month treatment outcomes); and to compare how these predictors, mediators, and moderators are similar or dissimilar within the normal comparison group. Aim 3 is to track the patterns of risk and protective factors (including their mediation or moderation by initial treatment assignment and/or outcome) involved in early and subsequent stages of developing substance-related disorders and antisocial behavior. Aim 4 is to examine the effect of initial treatment assignment and degree of treatment success on later academic performance, achievement, school conduct, tendency to drop out, and other adverse school outcomes.
In the original MTA design, patients were randomly assigned to 1 of 4 treatment conditions: (1) medication only; (2) psychosocial only; (3) combined (medication and psychosocial); or (4) Assessment-and-Referral condition. All but the latter were treated intensively for 14 months, with assessments for all subjects at baseline, 3, 9, 14, and 24 months. The original MTA design thus provides short-term (10 months post-treatment) follow-up at 24 months. This continuation extends the follow-up to assessments at 36, 60, and 84 months after treatment.
A child may be eligible for this study if he/she:
Is 7 - 9 years old, and has Attention Deficit Hyperactivity Disorder (ADHD).
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Attention Deficit Disorder With Hyperactivity Substance-related Disorders Dyssocial Behavior | Behavioral: Psychosocial treatment Drug: Anti-ADHD medication Behavioral: Assessment-and-Referral | Phase 4 |
This trial is a continuation of the Multimodal Treatment Study of Children with Attention Deficit Hyperactivity Disorder (MTA Study). Continuation Aim 1 is to track the persistence of intervention-related effects as the MTA sample matures into mid-adolescence, including subsequent mental-health and school-related service utilization patterns as a function of MTA treatment experience (treatment assignment) and outcome (degree of treatment success at 14 mo.). Aim 2 is to test specific hypotheses about predictors, mediators, and moderators of long-term outcome among children with ADHD (e.g., comorbidity; family functioning; cognitive skills; peer relations) that may influence adolescent functioning (either independent of or through initial treatment assignment and/or 14-month treatment outcomes); and to compare how these predictors, mediators, and moderators are similar or dissimilar within the normal comparison group. Aim 3 is to track the patterns of risk and protective factors (including their mediation or moderation by initial treatment assignment and/or outcome) involved in early and subsequent stages of developing substance-related disorders and antisocial behavior. Aim 4 is to examine the effect of initial treatment assignment and degree of treatment success on later academic performance, achievement, school conduct, tendency to drop out, and other adverse school outcomes.
In the original MTA design, patients were randomly assigned to 1 of 4 treatment conditions: (1) medication only; (2) psychosocial only; (3) combined (medication and psychosocial); or (4) Assessment-and-Referral condition. All but the latter were treated intensively for 14 months, with assessments for all subjects at baseline, 3, 9, 14, and 24 months. The original MTA design thus provides short-term (10 months post-treatment) follow-up at 24 months. This continuation extends the follow-up to assessments at 36, 60, and 84 months after treatment.
Study Type : | Interventional (Clinical Trial) |
Allocation: | Randomized |
Primary Purpose: | Treatment |
Official Title: | Multimodal Treatment Study of Children With ADHD |
Study Start Date : | September 1998 |
Study Completion Date : | November 1999 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 7 Years to 9 Years (Child) |
Sexes Eligible for Study: | All |
Inclusion Criteria:
-
Patients must have:
Rigorously diagnosed Attention Deficit Hyperactivity Disorder (ADHD).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000388
Principal Investigator: | Howard B. Abikoff, PhD | ||
Principal Investigator: | C. Keith Conners | ||
Principal Investigator: | Laurence L. Greenhill, MD | ||
Principal Investigator: | Stephen P. Hinshaw, PhD | ||
Principal Investigator: | William E. Pelham, PhD | ||
Principal Investigator: | James M. Swanson, PhD |
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00000388 |
Other Study ID Numbers: |
U01MH050453 ( U.S. NIH Grant/Contract ) U01MH050453 ( U.S. NIH Grant/Contract ) MH50447 MH50454 MH50461 MH50467 MH50440 DSIR CT |
First Posted: | November 3, 1999 Key Record Dates |
Last Update Posted: | September 29, 2015 |
Last Verified: | September 2015 |
Attention Deficit Disorder with Hyperactivity Adolescence Child Cognition Combined Modality Therapy Female Human |
Male Peer Group Risk Factors Treatment Outcome Attention Deficit Disorder with Hyperactivity -- *therapy Attention Deficit Disorder with Hyperactivity -- drug therapy Attention Deficit Disorder with Hyperactivity -- psychology |
Hyperkinesis Disease Substance-Related Disorders Attention Deficit Disorder with Hyperactivity Antisocial Personality Disorder Pathologic Processes Attention Deficit and Disruptive Behavior Disorders |
Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Chemically-Induced Disorders Personality Disorders |